C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
Public ClinicalTrials.gov record NCT00292981. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label Extension Study of CE1145 (Human Pasteurized C1 Esterase Inhibitor Concentrate) in Subjects With Congenital C1-INH Deficiency and Acute HAE Attacks
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of involvement of the larynx.The planned extension study is designed to enrol subjects that participated in the pivotal study in order to provide them with C1-INH for treatment of acute HAE attacks for 24 months or until the licensing procedure for C1-INH is finalized, whatever comes first.
Study identification
- NCT ID
- NCT00292981
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 57 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2005 (Type not available)
- Primary completion
- Feb 2010 (Actual)
- Completion
- May 2010 (Actual)
- Last update posted
- May 7, 2015
2005 – 2010
United States locations
- U.S. sites
- 13
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Contact CSL Behring for facility details | Weston | Florida | 33331 | — |
| Contact CSL Behring for facility details | Atlanta | Georgia | 30342 | — |
| Contact CSL Behring for facility details | Idaho Falls | Idaho | 83404 | — |
| Contact CSL Behring for facility details | Chicago | Illinois | 60612-3244 | — |
| Contact CSL Behring for facility details | Shreveport | Louisiana | 71130 | — |
| Contact CSL Behring for facility details | Boston | Massachusetts | 02115 | — |
| Contact CSL Behring for facility details | Plymouth | Minnesota | 55446 | — |
| Contact CSL Behring for facility details | Omaha | Nebraska | 69131 | — |
| Contact CSL Behring for facility details | Tulsa | Oklahoma | 74133 | — |
| Contact CSL Behring for facility details | Eugene | Oregon | 97401 | — |
| Contact CSL Behring for facility details | Hershey | Pennsylvania | 17033 | — |
| Contact CSL Behring for facility details | Rapid City | South Dakota | 57702 | — |
| Contact CSL Behring for facility details | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00292981, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2015 · Synced Nov 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00292981 live on ClinicalTrials.gov.